Haleon plc to buy back shares from Pfizer in £170 million deal

Today, Haleon plc (LSE/NYSE: HLN), a global leader in consumer health with a market capitalization of $46.09 billion and an impressive 27.66% return over the past year, announced an agreement to purchase approximately £170 million worth of its ordinary shares from Pfizer Inc. (NYSE:PFE) This transaction is part of a larger £500 million share buyback initiative for 2025 that Haleon disclosed on February 27, 2025.

The purchase, contingent upon the successful completion of Pfizer’s accelerated bookbuild offering to institutional investors, will be executed at an off-market price equivalent to the offering price per ordinary share. The final purchase price will match the share offering price, provided it does not exceed Haleon’s ordinary share price at today’s London Stock Exchange (LON:LSEG) closing. According to InvestingPro data, the stock is currently trading near its 52-week high of $10.80, reflecting strong market confidence.

Upon finalization of the purchase, Haleon intends to cancel the acquired shares, consistent with its capital allocation strategy. The company will release additional information following the outcome of Pfizer’s proposed offering. For deeper insights into Haleon’s financial health, which InvestingPro rates as "GOOD" with a comprehensive score of 2.87, subscribers can access the detailed Pro Research Report, along with 12+ exclusive ProTips.

Haleon’s portfolio includes well-known brands such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum, spanning across major categories like Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals and Supplements (VMS). The company maintains a healthy dividend yield of 2.26% and has demonstrated strong financial performance with an 8.07% year-to-date return.

This news is based on a press release statement and is for informational purposes only, not for distribution in jurisdictions where such dissemination would be unlawful.

In other recent news, Haleon plc disclosed its updated total number of shares and voting rights, reporting 9,083,725,919 ordinary shares issued, with 29,580,205 held in treasury. Consequently, the number of shares carrying voting rights stands at 9,054,145,714, a crucial figure for shareholders. Haleon also announced a board change, with Bryan Supran stepping down as a Non-Executive Director following Pfizer’s reduction of its stake in the company below 10%. Meanwhile, HSBC analyst Jeremy Fialko downgraded Haleon’s stock rating from Buy to Hold, maintaining a price target of GBP4.20 due to a 25% rise in share value and a subsequent increase in the forward price-to-earnings ratio.

Additionally, Haleon revealed share acquisitions by executives Adrian Morris and Tamara Rogers under the company’s Share Reward Plan. Each executive acquired 64 shares, aligning their interests with those of shareholders. These developments reflect Haleon’s ongoing transparency and governance efforts. Haleon is recognized for its portfolio of consumer health brands, including Advil, Sensodyne, and Centrum, as it continues to focus on enhancing everyday health.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.